By Steve Moore | Tuesday 18 January 2022
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Previously writing on “the UK’s leading independent tissue converter” Accrol (ACRL), last week with the shares falling to 25p I noted a further profit warning and a “strategic review” despite it arguing ‘timing issues’ and asked why no balance sheet numbers?. Now half-year results…